Skip to main content

Table 2 The quality assessment of included study using the Newcastle–Ottawa scale

From: Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Study

Selection

Comparability

Outcome

TOTAL

Quality

REC

SNEC

AE

DO

SC

AF

AO

FU

AFU

Ichihara 2020

1

1

1

1

0

0

1

0

1

6

Moderate

Wang 2019

1

1

1

1

0

0

1

0

1

6

Moderate

Popinat 2019

1

1

1

1

0

0

1

1

1

7

High

Naik 2019

1

1

1

1

0

0

1

1

1

7

High

Magri 2019

1

1

1

1

0

0

1

1

1

7

High

Labadie 2019

1

1

1

1

0

0

1

1

1

7

High

Kulkarni 2019

1

1

1

1

0

0

0

0

1

6

Moderate

Kichenadasse 2019

1

1

1

1

0

0

1

1

1

7

High

De Giorgi 2019

1

1

1

1

0

0

1

1

1

7

High

Cortellini 2019

1

1

1

1

0

0

1

0

1

6

Moderate

Richtig 2018

1

1

1

1

0

0

0

1

1

6

Moderate

Zhi 2018

1

1

1

1

0

0

0

0

1

5

Moderate

McQuade 2018

1

1

1

1

0

0

1

1

1

7

High

  1. REC, representativeness of the exposed cohort; SNEC, selection of the non-exposed cohort; AE, ascertainment of exposure; DO, demonstration that outcome of interest was not present at start of study; SC, study controls for age, sex; AF, study controls for any additional factors (chemoradiotherapy, curative resection); AO, assessment of outcome; FU, follow-up long enough (36 M) for outcomes to occur; AFU, adequacy of follow-up of cohorts. “1” means that the study is satisfied the item and “0” means the opposite situation